# 04 Hematopoietic Development and Malignancy Program

> **NIH NIH P30** · WASHINGTON UNIVERSITY · 2021 · $67,539

## Abstract

HEMATOPOIETIC DEVELOPMENT AND MALIGNANCY PROGRAM (HDMP): PROJECT SUMMARY
The long-term goals of the Hematopoietic Development and Malignancy Program (HDMP) are to identify basic
mechanisms regulating normal and malignant hematopoiesis, and develop innovative strategies to prevent,
stratify, and treat hematopoietic malignancies. The HDMP has 30 members from three departments at
Washington University School of Medicine. HDMP members are supported by $22.4 million direct costs in
cancer-related funding, including $5.3 million direct costs from the NCI and $4.5 million direct costs from other
peer-reviewed cancer-related funding. HDMP members published 760 papers during the current project period,
with 20% resulting from inter-programmatic collaborations, 26% from intra-programmatic collaborations, and
30% published in journals with an impact factor ≥10. HDMP members participated in 551 clinical trials involving
hematologic malignancies or stem cell transplantation, including 357 interventional trials. Basic science
translation remains a top priority for the HDMP. In the current project period, 25 investigator-initiated clinical trials
were developed from fundamental research performed (at least in part) at Siteman Cancer Center, including 22
investigator-initiated therapeutic interventional trials. Total interventional accruals were 2,961, of which 2,761
(93%) were interventional treatment. The interventional treatment accrual rate (as a function of reported
hematologic malignancy index cases) was 38% in 2018. Working groups in leukemia, lymphoma, myeloma, and
myelodysplastic syndromes/myeloproliferative neoplasms were established to develop, review, prioritize, and
conduct translational research. Each working group is organized around three themes: cancer genomics,
development of immunotherapies, and cancer biology. The HDMP fosters collaborative translational research
and trains junior investigators through research seminars, journal clubs, work-in-progress meetings, and an
annual retreat. Program leaders have identified areas of institutional strength and developed four specific
translational aims.
Aim 1: Leverage local expertise in cancer genomics to identify key genetic and epigenetic alterations in
hematopoietic malignancies and develop their translational potential.
Aim 2: Develop fundamental discoveries in immunology into novel immunotherapies targeting
hematopoietic malignancies. A particular area of focus is the development of novel cellular immunotherapies
for hematopoietic malignancies.
Aim 3: Translate fundamental discoveries in cancer cell biology into novel strategies to treat
hematopoietic malignancies and/or improve stem cell transplantation.
Aim 4: Identify and develop junior investigators in hematopoietic malignancies.

## Key facts

- **NIH application ID:** 10217018
- **Project number:** 5P30CA091842-20
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** TIMOTHY J. EBERLEIN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $67,539
- **Award type:** 5
- **Project period:** 2001-08-02 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10217018

## Citation

> US National Institutes of Health, RePORTER application 10217018, 04 Hematopoietic Development and Malignancy Program (5P30CA091842-20). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10217018. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*